SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Versaggi Shannon

(Last) (First) (Middle)
MANSELL OVERLOOK
300 COLONIAL CENTER PARKWAY, SUITE 600

(Street)
ROSWELL GA 30076

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/11/2023
3. Issuer Name and Ticker or Trading Symbol
SiteOne Landscape Supply, Inc. [ SITE ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP Marketing
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 2,110 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units (1) (1) Common Stock 591 (6) D
Restricted Share Units (2) (2) Common Stock 236 (6) D
Restricted Share Units (3) (3) Common Stock 451 (6) D
Restricted Share Units (4) (4) Common Stock 697 (6) D
Restricted Share Units (5) (5) Common Stock 1,339 (6) D
Stock Options (Right to Buy) (7) (7) Common Stock 5,903 (7) D
Stock Options (Right to Buy) (8) (8) Common Stock 7,094 (8) D
Stock Options (Right to Buy) (9) (9) Common Stock 3,114 (9) D
Stock Options (Right to Buy) (10) (10) Common Stock 2,963 (10) D
Stock Options (Right to Buy) (11) (11) Common Stock 2,811 (11) D
Explanation of Responses:
1. On February 17, 2020, the Reporting Person was granted 2,364 restricted stock units ("RSUs"), vesting in four equal annual installments beginning on February 17, 2021, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 1,773 of these RSUs had vested.
2. On February 17, 2020, the Reporting Person was granted 945 RSUs, vesting in four equal annual installments beginning on February 17, 2021, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 709 of these RSUs had vested.
3. On February 11, 2021, the Reporting Person was granted 902 RSUs, vesting in four equal annual installments beginning on February 11, 2022, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 451 of these RSUs had vested.
4. On February 10, 2022, the Reporting Person was granted 929 RSUs, vesting in four equal annual installments beginning on February 10, 2023, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 232 of these RSUs had vested.
5. On February 9, 2023, the Reporting Person was granted 1,339 RSUs, vesting in four equal annual installments beginning on February 9, 2024, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, none of these RSUs had vested.
6. RSUs convert into shares of Common Stock upon vesting on a one-for-one basis.
7. 5,903 options were granted on February 17, 2020, and vest and become exercisable ratably in four installments on each anniversary of February 17, 2020, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 4,427 of these options that remain outstanding had vested.
8. 7,094 options were granted on February 17, 2020, and vest and become exercisable ratably in four installments on each anniversary of February 17, 2020, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 5,321 of these options that remain outstanding had vested.
9. 3,114 options were granted on February 11, 2021, and vest and become exercisable ratably in four installments on each anniversary of February 11, 2021, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 1,557 of these options that remain outstanding had vested.
10. 2,963 options were granted on February 10, 2022, and vest and become exercisable ratably in four installments on each anniversary of February 10, 2022, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, 741 of these options that remain outstanding had vested.
11. 2,811 options were granted on February 9, 2023, and vest and become exercisable ratably in four installments on each anniversary of February 9, 2023, subject to the Reporting Person's continued employment. Prior to the filing of this Form 3, none of these options that remain outstanding had vested.
/s/ Briley Brisendine, Attorney-in-fact for Shannon Versaggi 05/15/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.